@article{8e9c2a972b664f15b20b4c4f615326e9,
title = "Management of castration-resistant, taxane-resistant prostate cancer",
abstract = "Metastatic castration-resistant prostate cancer that has become resistant to docetaxel chemotherapy represents one of the greatest clinical challenges in the management of this disease. Patients in this situation have an expected median survival that is typically less than 18 months, and they frequently suffer from symptoms related to progressive cancer and/or persistent treatment toxicity. More effective treatments for patients with taxane-resistant disease are desperately needed.",
author = "Beer, {Tomasz M.}",
note = "Funding Information: Dr. Beer receives research funding from Astellas, Boehringer Ingelheim, Bristol-Myers Squibb, Dendreon, Janssen Research & Development, Medivation, OncoGenex, Sotio, and Theraclone Sciences/OncoResponse; he has consulted for AbbVie, AstraZeneca, Churchill Pharmaceuticals, Clovis Oncology, Dendreon, F. Hoffmann-La Roche Ltd, Janssen (Biotech, Oncology, and Research & Development), Janssen Japan, and Johnson & Johnson; and he holds stock in Salarium Pharmaceuticals. Funding Information: Financial Disclosure: Dr. Beer receives research funding from Astellas, Boehringer Ingelheim, Publisher Copyright: {\textcopyright} 2017, UBM Medica Healthcare Publications. All rights reserved. Copyright: Copyright 2017 Elsevier B.V., All rights reserved.",
year = "2017",
month = aug,
day = "15",
language = "English (US)",
volume = "31",
pages = "1--5",
journal = "ONCOLOGY (United States)",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "8",
}